Urinary proteomics revealed prostaglandin H₂D-isomerase, not Zn-伪2-glycoprotein, as a biomarker for active lupus nephritis

详细信息	查看全文 | 推荐本文 |

• 作者：Poorichaya Somparn^a ; Nattiya Hirankarn^b ; ^c ; ^{Nattiyap@gmail.com} ; Asada Leelahavanichkul^c ; Weerapan Khovidhunkit^d ; Visith Thongboonkerd^e ; ^f ; Yingyos Avihingsanon^g ; ^{Yingyos.a@gmail.com}
• 关键词：LN ; lupus nephritis ; ZA2G ; Zn-alpha2-glycoprotein ; PGDS ; prostaglandin H2D-isomerase ; 2-DE ; two-dimensional gel electrophoresis ; SLE ; systemic lupus erythematosus ; SLEDAI-2K ; SLE Disease Activity Index 2000 ; ROC ; receiver operating characteristic curve.
• 刊名：Journal of Proteomics
• 出版年：2012
• 期刊代码：P37_18743919
• 类别：ch
• 出版时间：18 June, 2012
• 卷：75
• 期：11
• 页码：3240-3247
• 文件大小：689 K

摘要

Although renal histopathology is the gold standard for the diagnosis and prognosis of lupus nephritis (LN), the invasiveness of renal biopsy warrants the discovery of novel non-invasive diagnostic and prognostic biomarkers. In the present study, urine samples from 10 LN patients (5 active and 5 inactive) were analyzed by two-dimensional gel electrophoresis (2-DE) to screen for potential biomarkers of active LN. Quantitative analysis and statistics revealed 16 protein spots whose levels significantly differed between groups. These proteins were successfully identified by electrospray ionization quadrupole time-of-flight tandem mass spectrometry (ESI-Q-TOF MS/MS). Among these potential candidates, differential levels of urinary Zn-伪2-glycoprotein (ZA2G) and prostaglandin H₂D-isomerase (PGDS) were further validated by enzyme-linked immunosorbent assay (ELISA) in another independent group of 78 subjects, including 30 active LN, 26 inactive LN, 14 non-LN glomerular diseases, and 8 healthy normal individuals. Whereas ZA2G levels were elevated in urine of patients with active LN and non-LN glomerular diseases, PGDS was elevated only in the urine of the active LN group. Urinary PGDS, not ZA2G, may serve as a biomarker for active LN and upon validation in larger studies, may become the non-invasive test to evaluate the disease activity in future management of LN.